WIBA-AWARDS
26.5.2024 01:09:34 CEST | Business Wire | Press release
The sixth annual WIBA Awards for social media personalities on a mission to change the world took place on May 24th, 2024, at the iconic Hotel Martinez during the Cannes Film Festival. The event gathered hundreds of top global content creators responsible for the year’s most viral moments. The evening featured a cocktail reception, a Gala Dinner, and the Awards ceremony with a special performance by Sonique.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240525509294/en/
WIBA 2024 Winners (Photo: Business Wire)
The event awarded international celebrities and extraordinary personalities such as Coco Rocha, Lena Mahfouf (Situations), Alexandre Maras, Hyram, Sasha Ray and others. The Grand Prix WIBA title 2024 assigned to Burak Ozdemir, Turkish chef and restaurateur with over 129M followers on social media.
WIBA Awards were overseen by the World Influencers Association (WIBA) based in Monaco. It was the first and the only international award honoring the work of social media personalities across multiple categories.
WIBA Awards title holders are the top world influencers, such as Maye Musk, Richard Orlinski, Khaby Lame, Nusret Gökçe, Nikkie Tutorials, Gianluca Vacchi, Foodgod, Kat Graham, Kelly Rutherford, Ellen Von Unwerth and others.
WIBA Awards event highlighted the most followed social causes, empowered diverse influencers' voices, encouraged collaboration, and fostered a sense of a global community of peers. The typical instant reach of a WIBA Awards ballroom was over 200 million impressions.
WIBA 2024 Titles Holders 2024
Burak Özdemir: Grand Prix
Coco Rocha: Fashion Model Business Icon & Women Empowerment Advocate
Lena Situations: Motivation & Encouragement Lifestyle Influencer
Alexandre Maras: Most Influential Journalist in Social Media 2024
Hyram: Best Influential Skincare Expert
Mohamed Cheikh: French Contest Winners
Reem Khabbazeh: Most Influential Social Personality of Middle East
Lee Levi: Influential Actress in Social Media
Maxim Ivanchuk: Best Aesthetic Medicine Influencer
Esteriore Brothers: Best Entertainment Influencers
Max Mariola: Best Food Influencer
Sasha Ray: Fashion Lifestyle Influencer
Jeff Hamilton: Influential Celebrity Fashion Artist
Pietro Checchi: New Name of Italian Tiktok
Marcello D’Onofrio: Empowerment Celebrities Management Leader
Nadine Mirada: European Model Influencer
Daniel Asante: Social Media Model Influencer
Alex & Tom : Best Education Influencers
Elena Hazinah : Best Beauty Influencer
Angelina Usanova: Social Activity & Philanthropy Influencer
Francine Ehlke: Best Latin America Influencer
Youmna Khoury: Influential Beauty Business Leader
Urvashi Rautela: Influential Indian Star
PHOTOS: https://www.picdrop.com/gettyimagesit/6VAkztDsX3
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240525509294/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom